Abstract:Background Timely diagnosis of SARS-CoV-2 infection is the prerequisite for treatment and preventive quarantine. The serology characteristics and complement diagnosis value of antibody test to RNA test needs to be demonstrated. Method A patient cohort study was conducted at the first affiliated hospital of Zhejiang University, China. Serial plasma of COVID-19 patients and were collected and total antibody (Ab), IgM and IgG antibody against SARS-CoV-2 were detected. The antibody dynamics during the infection were described. Results The seroconversion rate for Ab, IgM and IgG in COVID-19 patients was 98.8% (79/80), 93.8% (75/80) and 93.8% (75/80), respectively. The first detectible serology marker is total antibody and followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 day post exposure (d.p.e) or 9, 10 and 12 days post onset, separately. The antibody levels increased rapidly since 6 d.p.o and accompanied with the decline of viral load. For patients in the early stage of illness (0-7d.p.o),Ab showed the highest sensitivity (64.1%) compared to the IgM and IgG (33.3% for both, p<0.001). The sensitivities of Ab, IgM and IgG detection increased to 100%, 96.7% and 93.3% two weeks later, respectively. Conclusions Typical acute antibody response is induced during the SARS-CoV-2 infection. The serology testing provides important complementation to RNA test for pathogenic specific diagnosis and helpful information to evaluate the adapted immunity status of patient. It should be strongly recommended to apply well-validated antibody tests in the clinical management and public health practice to improve the control of COVID-19 infection. Take-Home Message Antibody responses are induced after SARS-CoV-2 infection and complement diagnosis value of antibody test to RNA test was observed. Antibody tests are critical tools in clinical management and control of SARS-CoV-2 infection and COVID-19. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by China National Mega-Projects for Infectious Diseases (2017ZX10103008), and the Science and Technology Major Project of Xiamen (3502Z2020YJ01). ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes We will share individual participant data that underlie the results reported in this article after deidentification (text, tables, figures and appendices). The data will be available beginning 6 months after the major findings from the final analysis of the study were published, ending 2 years later. The data will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for individual participant data meta-analysis. Proposals should be directed to chenyuzy@zju.edu.cn. To gain access, data requestors will need to sign a data access agreement.

Previously Unrecognized Non-Reproducible Antibody-Antigen Interactions and Their Implications for Diagnosis of Viral Infections Including COVID-19

Previously Unrecognized Nonreproducible Antibody-Probe Interactions

Removing Negative Impacts from Inevitable Nonreproducible and Nonspecific Antibody-Probe Interactions in Viral Serology

Proteomics Investigation of Diverse Serological Patterns in COVID-19

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Experimental Validation and Broader Implications for Correlates of Protection

Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy

Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset

Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Evaluating the value of anti-SARS-CoV-2 antibody detection and neutralizing responses with euvirus: a population of 10776 close contacts in the epidemic of Fujian

Unspecific reactivity must be excluded in COVID-19 epidemiological analyses or virus tracing based on serologic testing: Analysis of 46,777 post-pandemic samples and 1,114 pre-pandemic samples

High-specificity targets in SARS-CoV-2 N protein for serological detection and distinction from SARS-CoV

Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2

An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity

Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory Markers in a COVID-19 Cohort